Pharmacokinetics of drugs in cachectic patients: A systematic review

Katja Trobec, Mojca Kerec Kos, Stephan Von Haehling, Jochen Springer, Stefan D. Anker, Mitja Lainscak

Research output: Contribution to journalArticle

Abstract

Cachexia is a weight-loss process caused by an underlying chronic disease such as cancer, chronic heart failure, chronic obstructive pulmonary disease, or rheumatoid arthritis. It leads to changes in body structure and function that may influence the pharmacokinetics of drugs. Changes in gut function and decreased subcutaneous tissue may influence the absorption of orally and transdermally applied drugs. Altered body composition and plasma protein concentration may affect drug distribution. Changes in the expression and function of metabolic enzymes could influence the metabolism of drugs, and their renal excretion could be affected by possible reduction in kidney function. Because no general guidelines exist for drug dose adjustments in cachectic patients, we conducted a systematic search to identify articles that investigated the pharmacokinetics of drugs in cachectic patients.

Original languageEnglish
Article numbere79603
JournalPLoS One
Volume8
Issue number11
DOIs
Publication statusPublished - Nov 8 2013

Fingerprint

Pharmacokinetics
systematic review
pharmacokinetics
drugs
Pharmaceutical Preparations
cachexia
rheumatoid arthritis
renal function
heart failure
Pulmonary diseases
Cachexia
chronic diseases
respiratory tract diseases
Subcutaneous Tissue
blood proteins
body composition
Body Composition
Metabolism
weight loss
digestive system

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Trobec, K., Kos, M. K., Von Haehling, S., Springer, J., Anker, S. D., & Lainscak, M. (2013). Pharmacokinetics of drugs in cachectic patients: A systematic review. PLoS One, 8(11), [e79603]. https://doi.org/10.1371/journal.pone.0079603

Pharmacokinetics of drugs in cachectic patients : A systematic review. / Trobec, Katja; Kos, Mojca Kerec; Von Haehling, Stephan; Springer, Jochen; Anker, Stefan D.; Lainscak, Mitja.

In: PLoS One, Vol. 8, No. 11, e79603, 08.11.2013.

Research output: Contribution to journalArticle

Trobec, K, Kos, MK, Von Haehling, S, Springer, J, Anker, SD & Lainscak, M 2013, 'Pharmacokinetics of drugs in cachectic patients: A systematic review', PLoS One, vol. 8, no. 11, e79603. https://doi.org/10.1371/journal.pone.0079603
Trobec K, Kos MK, Von Haehling S, Springer J, Anker SD, Lainscak M. Pharmacokinetics of drugs in cachectic patients: A systematic review. PLoS One. 2013 Nov 8;8(11). e79603. https://doi.org/10.1371/journal.pone.0079603
Trobec, Katja ; Kos, Mojca Kerec ; Von Haehling, Stephan ; Springer, Jochen ; Anker, Stefan D. ; Lainscak, Mitja. / Pharmacokinetics of drugs in cachectic patients : A systematic review. In: PLoS One. 2013 ; Vol. 8, No. 11.
@article{b5d0f45bcfb54bea8577af36f1e21c39,
title = "Pharmacokinetics of drugs in cachectic patients: A systematic review",
abstract = "Cachexia is a weight-loss process caused by an underlying chronic disease such as cancer, chronic heart failure, chronic obstructive pulmonary disease, or rheumatoid arthritis. It leads to changes in body structure and function that may influence the pharmacokinetics of drugs. Changes in gut function and decreased subcutaneous tissue may influence the absorption of orally and transdermally applied drugs. Altered body composition and plasma protein concentration may affect drug distribution. Changes in the expression and function of metabolic enzymes could influence the metabolism of drugs, and their renal excretion could be affected by possible reduction in kidney function. Because no general guidelines exist for drug dose adjustments in cachectic patients, we conducted a systematic search to identify articles that investigated the pharmacokinetics of drugs in cachectic patients.",
author = "Katja Trobec and Kos, {Mojca Kerec} and {Von Haehling}, Stephan and Jochen Springer and Anker, {Stefan D.} and Mitja Lainscak",
year = "2013",
month = "11",
day = "8",
doi = "10.1371/journal.pone.0079603",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetics of drugs in cachectic patients

T2 - A systematic review

AU - Trobec, Katja

AU - Kos, Mojca Kerec

AU - Von Haehling, Stephan

AU - Springer, Jochen

AU - Anker, Stefan D.

AU - Lainscak, Mitja

PY - 2013/11/8

Y1 - 2013/11/8

N2 - Cachexia is a weight-loss process caused by an underlying chronic disease such as cancer, chronic heart failure, chronic obstructive pulmonary disease, or rheumatoid arthritis. It leads to changes in body structure and function that may influence the pharmacokinetics of drugs. Changes in gut function and decreased subcutaneous tissue may influence the absorption of orally and transdermally applied drugs. Altered body composition and plasma protein concentration may affect drug distribution. Changes in the expression and function of metabolic enzymes could influence the metabolism of drugs, and their renal excretion could be affected by possible reduction in kidney function. Because no general guidelines exist for drug dose adjustments in cachectic patients, we conducted a systematic search to identify articles that investigated the pharmacokinetics of drugs in cachectic patients.

AB - Cachexia is a weight-loss process caused by an underlying chronic disease such as cancer, chronic heart failure, chronic obstructive pulmonary disease, or rheumatoid arthritis. It leads to changes in body structure and function that may influence the pharmacokinetics of drugs. Changes in gut function and decreased subcutaneous tissue may influence the absorption of orally and transdermally applied drugs. Altered body composition and plasma protein concentration may affect drug distribution. Changes in the expression and function of metabolic enzymes could influence the metabolism of drugs, and their renal excretion could be affected by possible reduction in kidney function. Because no general guidelines exist for drug dose adjustments in cachectic patients, we conducted a systematic search to identify articles that investigated the pharmacokinetics of drugs in cachectic patients.

UR - http://www.scopus.com/inward/record.url?scp=84892516555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892516555&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0079603

DO - 10.1371/journal.pone.0079603

M3 - Article

C2 - 24282510

AN - SCOPUS:84892516555

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e79603

ER -